MA27205A1 - Preparations d'insuline acides presentant une stabilite amelioree - Google Patents

Preparations d'insuline acides presentant une stabilite amelioree

Info

Publication number: MA27205A1
Authority: MA; Morocco
Prior art keywords: improved stability; insulin preparations; acid insulin; acid; preparations
Prior art date: 2002-06-18

Application number

MA27953A

Other languages

English (en)

Inventor

Anette Brunner-Schwarz

Norbert Lill

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-18

Filing date

2004-11-16

Publication date

2005-01-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29723248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27205(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-16 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2005-01-03 Publication of MA27205A1 publication Critical patent/MA27205A1/fr

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
239000002253 acid Substances 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
238000002360 preparation method Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Biochemistry (AREA)
Obesity (AREA)
Hematology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

MA27953A 2002-06-18 2004-11-16 Preparations d'insuline acides presentant une stabilite amelioree MA27205A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10227232A DE10227232A1 (de)	2002-06-18	2002-06-18	Saure Insulinzubereitungen mit verbesserter Stabilität

Publications (1)

Publication Number	Publication Date
MA27205A1 true MA27205A1 (fr)	2005-01-03

Family

ID=29723248

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA27953A MA27205A1 (fr)	2002-06-18	2004-11-16	Preparations d'insuline acides presentant une stabilite amelioree

Country Status (38)

Country	Link
US (4)	US20040048783A1 (fr)
EP (2)	EP2305288B1 (fr)
JP (2)	JP5237522B2 (fr)
KR (1)	KR101040029B1 (fr)
CN (2)	CN102133393B (fr)
AR (1)	AR039688A1 (fr)
AU (1)	AU2003238471B2 (fr)
BR (1)	BRPI0311877B8 (fr)
CA (1)	CA2490116C (fr)
CR (1)	CR7614A (fr)
CY (1)	CY1113537T1 (fr)
DE (1)	DE10227232A1 (fr)
DK (1)	DK1517697T3 (fr)
EC (1)	ECSP045496A (fr)
ES (2)	ES2817879T3 (fr)
HN (1)	HN2003000184A (fr)
HR (1)	HRP20041200B1 (fr)
IL (1)	IL165788A (fr)
MA (1)	MA27205A1 (fr)
ME (1)	MEP28708A (fr)
MX (1)	MXPA04012233A (fr)
MY (1)	MY142354A (fr)
NO (1)	NO328567B1 (fr)
NZ (1)	NZ537211A (fr)
OA (1)	OA12870A (fr)
PA (1)	PA8575701A1 (fr)
PE (1)	PE20040560A1 (fr)
PL (1)	PL208773B1 (fr)
PT (2)	PT2305288T (fr)
RS (1)	RS52388B (fr)
RU (1)	RU2313362C2 (fr)
SV (1)	SV2004001556A (fr)
TN (1)	TNSN04249A1 (fr)
TW (1)	TWI315201B (fr)
UA (1)	UA79477C2 (fr)
UY (1)	UY27854A1 (fr)
WO (1)	WO2003105888A1 (fr)
ZA (1)	ZA200409273B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
ES2328048T3 (es) *	2004-03-12	2009-11-06	Biodel, Inc.	Composiciones de insulina con absorcion mejorada.
EP1758540A4 (fr) *	2004-05-24	2007-06-20	Wockhardt Ltd	Purification d'un materiau du type insuline par chromatographie en phase inverse
UA75030C2 (en) *	2005-11-30	2006-03-15	Viktor Oleksandrovych Bykov	Method for obtaining stable aqueous solutions of drugs
WO2007135117A2 (fr) *	2006-05-24	2007-11-29	Novo Nordisk A/S	Formulations solubles stables contenant de l'insuline
DE102006031955A1 (de)	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de)	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Amidiertes Insulin Glargin
US20100120660A1 (en) *	2007-04-30	2010-05-13	Per Balschmidt	Highly concentrated insulin solutions and compositions
JP5352596B2 (ja) *	2008-01-04	2013-11-27	バイオデル，インコーポレイテッド	組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤
CA2711752A1 (fr)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Nouveaux derives d'insuline a profil temporel/d'action extremement retarde
DK2229407T3 (en)	2008-01-09	2017-02-27	Sanofi Aventis Deutschland	NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
PL2331075T3 (pl) *	2008-08-29	2016-04-29	Genzyme Corp	Formulacje peptydowe o kontrolowanym uwalnianiu
US20100069292A1 (en) *	2008-09-02	2010-03-18	Biodel, Inc.	Insulin with a basal release profile
CN103736082A (zh)	2008-10-17	2014-04-23	赛诺菲-安万特德国有限公司	胰岛素和glp-1激动剂的组合
US9060927B2 (en) *	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
PH12011502708B1 (en) *	2009-07-06	2017-11-10	Sanofi Aventis Deutschland	Insulin preparations containing methionine
AU2010317995B2 (en)	2009-11-13	2014-04-17	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh)	2009-11-13	2015-09-16	赛诺菲-安万特德国有限公司	包含glp-1激动剂和甲硫氨酸的药物组合物
TW201138808A (en)	2010-05-03	2011-11-16	Bristol Myers Squibb Co	Serum albumin binding molecules
US8637458B2 (en)	2010-05-12	2014-01-28	Biodel Inc.	Insulin with a stable basal release profile
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
WO2011156476A2 (fr) *	2010-06-08	2011-12-15	Biodel Inc.	Insuline présentant un profil de libération basal
PT2611458T (pt)	2010-08-30	2016-12-16	Sanofi Aventis Deutschland	Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
CN102188367B (zh) *	2011-01-05	2012-11-07	山东新时代药业有限公司	一种甘精胰岛素注射液及其制备方法
KR20140043709A (ko)	2011-01-20	2014-04-10	질랜드 파마 에이/에스	아실화 글루카곤 유사체와 인슐린 유사체의 조합
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
DK2741765T3 (en) *	2011-08-10	2016-06-13	Adocia	Injectable solution of at least one type of basal insulin
ES2550357T3 (es)	2011-08-29	2015-11-06	Sanofi-Aventis Deutschland Gmbh	Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2771300B1 (fr)	2011-10-25	2017-12-20	Corning Incorporated	Récipients pharmaceutiques en verre résistant au délaminage et contenant des principes pharmaceutiques actifs
US10350139B2 (en)	2011-10-25	2019-07-16	Corning Incorporated	Pharmaceutical glass packaging assuring pharmaceutical sterility
BR112014016889A8 (pt)	2012-01-09	2017-07-04	Adocia	composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
US20150314003A2 (en)	2012-08-09	2015-11-05	Adocia	Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014076423A1 (fr)	2012-11-13	2014-05-22	Adocia	Formulation à action rapide d'insuline comprenant un composé anionique substitué
CN104994864B (zh) *	2012-12-19	2018-05-29	沃克哈特有限公司	包含人胰岛素或其类似物或衍生物的稳定水性组合物
MX2015008114A (es)	2012-12-21	2015-11-06	Sanofi Sa	Derivados de exendina-4.
CN104870469A (zh)	2012-12-26	2015-08-26	沃克哈特有限公司	药物组合物
TWI641381B (zh) *	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
CN110354255B (zh)	2013-04-03	2024-05-14	赛诺菲	通过长效胰岛素制剂治疗糖尿病
US9839579B2 (en)	2013-04-24	2017-12-12	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en)	2013-04-24	2017-12-26	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en)	2013-04-24	2017-03-28	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en)	2013-04-24	2017-07-18	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en)	2013-04-24	2017-07-25	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en)	2013-04-24	2017-08-01	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en)	2013-04-24	2017-07-18	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en)	2013-04-24	2017-07-18	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en)	2013-04-24	2017-08-01	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3080152A1 (fr)	2013-12-13	2016-10-19	Sanofi	Analogues peptidiques de l'exendine 4 non acylés
WO2015086729A1 (fr)	2013-12-13	2015-06-18	Sanofi	Agonistes mixtes des récepteurs glp-1/gip
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (fr)	2013-12-13	2018-08-01	Sanofi	Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double
RU2016132342A (ru)	2014-01-09	2018-02-14	Санофи	Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
KR20160104726A (ko)	2014-01-09	2016-09-05	사노피	인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
JP6735674B2 (ja)	2014-01-09	2020-08-05	サノフイＳａｎｏｆｉ	インスリンアスパルトの安定化された医薬製剤
JP7173953B2 (ja) *	2014-01-09	2022-11-16	サノフイ	インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
CR20160376A (es)	2014-01-20	2016-10-07	Hanmi Pharm Ind Co Ltd	Insulina de acción prolongada y uso de la misma
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
AR100639A1 (es)	2014-05-29	2016-10-19	Hanmi Pharm Ind Co Ltd	Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh)	2014-05-30	2020-02-11	南韓商韓美藥品股份有限公司	包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
UA123763C2 (uk) *	2014-10-23	2021-06-02	Енджіем Байофармасьютикалз, Інк.	Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
KR102578030B1 (ko)	2014-12-12	2023-09-14	사노피-아벤티스 도이칠란트 게엠베하	인슐린 글라진／릭시세나티드 고정비 제형
TW201630622A (zh)	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JO3749B1 (ar)	2015-08-27	2021-01-31	Lilly Co Eli	تركيبات إنسولين سريعة المفعول
UY36870A (es)	2015-08-28	2017-03-31	Hanmi Pharm Ind Co Ltd	Análogos de insulina novedosos
WO2017179615A1 (fr) *	2016-04-15	2017-10-19	富士フイルム株式会社	Réseau de micro-aiguilles et procédé de fabrication d'un réseau de micro-aiguilles
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
KR102698929B1 (ko)	2016-09-23	2024-08-27	한미약품 주식회사	인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
EP3518893A1 (fr)	2016-09-29	2019-08-07	Arecor Limited	Nouvelles formulations
AR111341A1 (es)	2017-03-23	2019-07-03	Hanmi Pharm Ind Co Ltd	Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
MX2019014195A (es)	2017-06-01	2020-01-27	Lilly Co Eli	Composiciones de insulina de rapida accion.
US12357562B2 (en)	2018-04-04	2025-07-15	Arecor Limited	Injection pen system for the delivery of an insulin compound
WO2020239837A1 (fr) *	2019-05-29	2020-12-03	Sanofi	Dispositif d'administration de médicament

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3868358A (en) *	1971-04-30	1975-02-25	Lilly Co Eli	Protamine-insulin product
US3758683A (en) *	1971-04-30	1973-09-11	R Jackson	Insulin product
US4153689A (en) *	1975-06-13	1979-05-08	Takeda Chemical Industries, Ltd.	Stable insulin preparation for nasal administration
GB1554157A (en)	1975-06-13	1979-10-17	Takeda Chemical Industries Ltd	Stable insulin preparation for intra nasal administration
GB1527605A (en) *	1975-08-20	1978-10-04	Takeda Chemical Industries Ltd	Insulin preparation for intranasal administration
JPS52156913A (en) *	1976-06-21	1977-12-27	Toko Yakuhin Kogyo Kk	Production of injectionable medicine
US4783441A (en) *	1979-04-30	1988-11-08	Hoechst Aktiengesellschaft	Aqueous protein solutions stable to denaturation
EP0018609B1 (fr)	1979-04-30	1983-09-21	Hoechst Aktiengesellschaft	Solutions aqueuses de protéines, stables à la dénaturation, procédé pour leur fabrication et leur utilisation
JPS55153712A (en) *	1979-05-18	1980-11-29	Kao Corp	Insulin pharmaceutical preparation and its production
DE3033127A1 (de)	1980-09-03	1982-04-08	Hoechst Ag, 6000 Frankfurt	Neue analoga des insulins
IE52535B1 (en) *	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
AU558474B2 (en)	1981-07-17	1987-01-29	Nordisk Insulinlaboratorium	A stable aqueous, therapeutic insulin preparation and a process for preparing it
NL193099C (nl) *	1981-10-30	1998-11-03	Novo Industri As	Gestabiliseerde insuline-oplossing.
DE3316363A1 (de)	1983-05-05	1984-11-08	Deutsche Babcock Anlagen Ag, 4200 Oberhausen	Walzenrost fuer muellverbrennungsanlagen
DE3326473A1 (de) *	1983-07-22	1985-01-31	Hoechst Ag, 6230 Frankfurt	Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) *	1983-07-22	1985-02-14	Hoechst Ag, 6230 Frankfurt	Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) *	1983-07-29	1985-02-07	Hoechst Ag, 6230 Frankfurt	Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US5177068A (en) *	1984-04-19	1993-01-05	National Research Development Corporation	Pharmaceutical compositions
US4839341A (en) *	1984-05-29	1989-06-13	Eli Lilly And Company	Stabilized insulin formulations
CA1244347A (fr)	1984-05-29	1988-11-08	Eddie H. Massey	Formule d'insuline stabilisee
DE3576120D1 (de) *	1984-06-09	1990-04-05	Hoechst Ag	Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
DE3440988A1 (de)	1984-11-09	1986-07-10	Hoechst Ag, 6230 Frankfurt	Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
US5008241A (en) *	1985-03-12	1991-04-16	Novo Nordisk A/S	Novel insulin peptides
DK113585D0 (da)	1985-03-12	1985-03-12	Novo Industri As	Nye peptider
DK347086D0 (da)	1986-07-21	1986-07-21	Novo Industri As	Novel peptides
EP0200383A3 (fr)	1985-04-15	1987-09-02	Eli Lilly And Company	Procédé pour administrer l'insuline
DE3526995A1 (de)	1985-07-27	1987-02-05	Hoechst Ag	Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
PH25772A (en)	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
DE3541856A1 (de)	1985-11-27	1987-06-04	Hoechst Ag	Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
US5496924A (en) *	1985-11-27	1996-03-05	Hoechst Aktiengesellschaft	Fusion protein comprising an interleukin-2 fragment ballast portion
CA1275922C (fr)	1985-11-28	1990-11-06	Harunobu Amagase	Traitement du cancer
DE3544295A1 (de)	1985-12-14	1987-06-19	Bayer Ag	Thermoplastische formmassen mit hoher kriechstromfestigkeit
FI884914A0 (fi)	1987-02-25	1988-10-24	Novo Industri As	Nya insulinderivat.
US5034415A (en) *	1987-08-07	1991-07-23	Century Laboratories, Inc.	Treatment of diabetes mellitus
DE3726655A1 (de) *	1987-08-11	1989-02-23	Hoechst Ag	Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
DK257988D0 (da)	1988-05-11	1988-05-11	Novo Industri As	Nye peptider
DE3827533A1 (de)	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) *	1988-11-08	1990-05-10	Hoechst Ag	Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5210038A (en) *	1988-12-22	1993-05-11	Becton, Dickinson And Company	Multiplate subculture solid media devices
JPH04502465A (ja)	1988-12-23	1992-05-07	ノボ　ノルディスク　アクティーゼルスカブ	ヒトインシュリン類似物質
US4994439A (en) *	1989-01-19	1991-02-19	California Biotechnology Inc.	Transmembrane formulations for drug administration
IL93282A (en)	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogues
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
US4886164A (en) *	1989-06-16	1989-12-12	Enviro Med, Inc.	Containers for medical waste
US5358857A (en) *	1989-08-29	1994-10-25	The General Hospital Corp.	Method of preparing fusion proteins
DK0532546T3 (da) *	1990-05-10	1998-12-28	Nycomed Pharma As	Farmaceutisk præparat indeholdende N-glycofuroler og N-ethylenglycoler
US5397771A (en) *	1990-05-10	1995-03-14	Bechgaard International Research And Development A/S	Pharmaceutical preparation
DK155690D0 (da) *	1990-06-28	1990-06-28	Novo Nordisk As	Nye peptider
DK10191D0 (da) *	1991-01-22	1991-01-22	Novo Nordisk As	Hidtil ukendte peptider
DE4140186C2 (de) *	1991-12-05	1996-07-04	Alfatec Pharma Gmbh	Perorale Applikationsform für Peptidarzneistoffe, insbesondere Insulin
US6468959B1 (en) *	1991-12-05	2002-10-22	Alfatec-Pharm Gmbh	Peroral dosage form for peptide containing medicaments, in particular insulin
US5614219A (en) *	1991-12-05	1997-03-25	Alfatec-Pharma Gmbh	Oral administration form for peptide pharmaceutical substances, in particular insulin
DE59305396D1 (de) *	1992-12-02	1997-03-20	Hoechst Ag	Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
AU680462B2 (en)	1992-12-18	1997-07-31	Eli Lilly And Company	Insulin analogs
JP2743761B2 (ja) *	1993-03-19	1998-04-22	松下電器産業株式会社	走査型プローブ顕微鏡および原子種同定方法
US5514656A (en) *	1993-05-28	1996-05-07	Abbott Laboratories	Method of providing enteral nutritional support for patients undergoing radiation therapy and/or chemotherapy
US5882944A (en)	1993-06-23	1999-03-16	The Regents Of The University Of California	Methods for G protein coupled receptor activity screening
US5506203C1 (en) *	1993-06-24	2001-02-06	Astra Ab	Systemic administration of a therapeutic preparation
EP0637073A1 (fr) *	1993-07-29	1995-02-01	STMicroelectronics S.r.l.	Procédé de réalisation de transistors M.O.S. à canaux P pour dispositifs complémentairs (CMOS)
US5534488A (en) *	1993-08-13	1996-07-09	Eli Lilly And Company	Insulin formulation
DE4405179A1 (de) *	1994-02-18	1995-08-24	Hoechst Ag	Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
DE4406467A1 (de) *	1994-02-23	1995-08-24	Dragoco Gerberding Co Ag	Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5559094A (en) *	1994-08-02	1996-09-24	Eli Lilly And Company	AspB1 insulin analogs
EP0779806B2 (fr)	1994-09-09	2008-04-16	Takeda Pharmaceutical Company Limited	Preparation a liberation prolongee renfermant un sel metal de peptide
US5547929A (en) *	1994-09-12	1996-08-20	Eli Lilly And Company	Insulin analog formulations
US5707641A (en) *	1994-10-13	1998-01-13	Pharmaderm Research & Development Ltd.	Formulations comprising therapeutically-active proteins or polypeptides
US5496164A (en) *	1994-10-20	1996-03-05	The Conair Group, Inc.	In-line tubing die
US5824638A (en) *	1995-05-22	1998-10-20	Shire Laboratories, Inc.	Oral insulin delivery
JP2002514892A (ja)	1995-06-08	2002-05-21	コブラセラピューティクスリミテッド	遺伝子治療における合成ウイルス様粒子の使用
WO1997001331A2 (fr)	1995-06-27	1997-01-16	Takeda Chemical Industries, Ltd.	Production de preparations a liberation prolongee
JPH11292787A (ja) *	1995-08-15	1999-10-26	Asahi Chem Ind Co Ltd	生理活性ペプチドを含有する経粘膜投与製剤
DE19545257A1 (de) *	1995-11-24	1997-06-19	Schering Ag	Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5985309A (en) *	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US5948751A (en) *	1996-06-20	1999-09-07	Novo Nordisk A/S	X14-mannitol
US5656772A (en) *	1996-07-19	1997-08-12	Markel; Philip A.	Gas pressure gauge clamp
US5783556A (en) *	1996-08-13	1998-07-21	Genentech, Inc.	Formulated insulin-containing composition
US6043214A (en) *	1997-03-20	2000-03-28	Novo Nordisk A/S	Method for producing powder formulation comprising an insulin
BR9808285A (pt)	1997-03-20	2000-05-16	Novo Nordisk As	Cristais de insulina isentos de zinco, formulação terapêutica em pó, processo para a preparação de cristais de insulina isentos de zinco, uso de cristais isentos de zinco, e, processo para o tratamento de diabetes mellitus
US6310038B1 (en) *	1997-03-20	2001-10-30	Novo Nordisk A/S	Pulmonary insulin crystals
CO4750643A1 (es)	1997-06-13	1999-03-31	Lilly Co Eli	Formulacion estable de la insulina que contiene l-arginina y protamina
ZA989744B (en) *	1997-10-31	2000-04-26	Lilly Co Eli	Method for administering acylated insulin.
AU1375199A (en)	1997-11-12	1999-05-31	Alza Corporation	Method for decreasing self-association of polypeptides
EP1044016B1 (fr) *	1998-01-09	2005-03-16	Novo Nordisk A/S	Compositions d'insuline stabilisees
US6211144B1 (en) *	1998-10-16	2001-04-03	Novo Nordisk A/S	Stable concentrated insulin preparations for pulmonary delivery
HUP0104111A3 (en)	1998-10-16	2002-05-28	Novo Nordisk As	Stable concentrated insulin preparations for pulmonary delivery
IL142002A0 (en)	1998-10-16	2002-03-10	Novo Nordisk As	Insulin preparation for pulmonary delivery containing menthol
JP2002529514A (ja)	1998-11-18	2002-09-10	ノボノルディスクアクティーゼルスカブ	フェノール及びクレゾールを要さない安定なインスリン水性調製物
US6489292B1 (en) *	1998-11-18	2002-12-03	Novo Nordisk A/S	Stable aqueous insulin preparations without phenol and cresol
DE19908041A1 (de) *	1999-02-24	2000-08-31	Hoecker Hartwig	Kovalent verbrückte Insulindimere
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000074736A1 (fr)	1999-06-04	2000-12-14	Delrx Pharmaceutical Corporation	Formulations comprenant des particules deshydratees d'agents pharmaceutiques et leur procede de preparation
WO2001000223A2 (fr)	1999-06-25	2001-01-04	Minimed Inc.	Therapie anti diabete a agents multiples
US6309663B1 (en) *	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
JP2003509453A (ja)	1999-09-21	2003-03-11	アールティーピー・ファーマ・インコーポレーテッド	生物学的に活性な物質の、表面改質された粒状組成物
US6720001B2 (en) *	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
ATE288765T1 (de)	1999-12-16	2005-02-15	Lilly Co Eli	Polypeptidzusammensetzungen mit verbesserter stabilität
AU2001220765A1 (en)	2000-01-24	2001-07-31	Medtronic Minimed, Inc.	Mixed buffer system for stabilizing polypeptide formulations
JP4711520B2 (ja) *	2000-03-21	2011-06-29	日本ケミカルリサーチ株式会社	生理活性ペプチド含有粉末
US6267481B1 (en) *	2000-04-05	2001-07-31	Jeng Tai Umbrella Mfg., Corp.	Illumination assembly for an umbrella
WO2001093837A2 (fr)	2000-06-08	2001-12-13	Eli Lilly And Company	Poudre proteinique administree par voie pulmonaire
KR100508695B1 (ko)	2001-02-13	2005-08-17	한국과학기술연구원	인슐린의 경구투여용 제형과 그의 제조방법
DE10114178A1 (de) *	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CN1160122C (zh) *	2001-04-20	2004-08-04	清华大学	一种制备口服胰岛素油相制剂的方法
WO2003035051A2 (fr)	2001-10-19	2003-05-01	Inhale Therapeutic Systems, Inc.	Utilisation d'agents sequestrants des protons dans des formulations medicamenteuses
WO2003035028A1 (fr)	2001-10-19	2003-05-01	Nektar Therapeutics	Modulation de la densite de charge pour ameliorer les caracteristiques de proteines sechees par pulverisation
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
US6960551B2 (en) *	2002-08-23	2005-11-01	Exxonmobil Research And Engineering Company	Functionalized periodic mesoporous materials, their synthesis and use
US6906897B1 (en) *	2003-02-28	2005-06-14	Western Digital Technologies, Inc.	Disk drive including an actuator main coil and an actuator secondary coil with a lateral segment and method of operating same

2002
- 2002-06-18 DE DE10227232A patent/DE10227232A1/de not_active Ceased
2003
- 2003-05-06 UA UAA200500437A patent/UA79477C2/uk unknown
- 2003-06-05 EP EP10178842.0A patent/EP2305288B1/fr not_active Expired - Lifetime
- 2003-06-05 ME MEP-287/08A patent/MEP28708A/xx unknown
- 2003-06-05 ES ES10178842T patent/ES2817879T3/es not_active Expired - Lifetime
- 2003-06-05 WO PCT/EP2003/005887 patent/WO2003105888A1/fr not_active Ceased
- 2003-06-05 CN CN201110056210.9A patent/CN102133393B/zh not_active Expired - Lifetime
- 2003-06-05 PT PT101788420T patent/PT2305288T/pt unknown
- 2003-06-05 DK DK03732536.2T patent/DK1517697T3/da active
- 2003-06-05 RS YU105704A patent/RS52388B/sr unknown
- 2003-06-05 JP JP2004512789A patent/JP5237522B2/ja not_active Expired - Lifetime
- 2003-06-05 PT PT37325362T patent/PT1517697E/pt unknown
- 2003-06-05 CA CA2490116A patent/CA2490116C/fr not_active Expired - Lifetime
- 2003-06-05 MX MXPA04012233A patent/MXPA04012233A/es active IP Right Grant
- 2003-06-05 BR BRPI0311877A patent/BRPI0311877B8/pt active IP Right Grant
- 2003-06-05 ES ES03732536T patent/ES2397158T3/es not_active Expired - Lifetime
- 2003-06-05 NZ NZ537211A patent/NZ537211A/en not_active IP Right Cessation
- 2003-06-05 EP EP03732536A patent/EP1517697B1/fr not_active Expired - Lifetime
- 2003-06-05 OA OA1200400332A patent/OA12870A/en unknown
- 2003-06-05 RU RU2005100959/15A patent/RU2313362C2/ru not_active IP Right Cessation
- 2003-06-05 PL PL372072A patent/PL208773B1/pl unknown
- 2003-06-05 HR HRP20041200AA patent/HRP20041200B1/hr not_active IP Right Cessation
- 2003-06-05 KR KR1020047020482A patent/KR101040029B1/ko not_active Expired - Lifetime
- 2003-06-05 AU AU2003238471A patent/AU2003238471B2/en not_active Expired
- 2003-06-05 CN CN038138107A patent/CN1662252A/zh active Pending
- 2003-06-11 PE PE2003000581A patent/PE20040560A1/es not_active Application Discontinuation
- 2003-06-13 PA PA20038575701A patent/PA8575701A1/es unknown
- 2003-06-13 US US10/461,740 patent/US20040048783A1/en not_active Abandoned
- 2003-06-16 SV SV2003001556A patent/SV2004001556A/es not_active Application Discontinuation
- 2003-06-16 TW TW092116208A patent/TWI315201B/zh not_active IP Right Cessation
- 2003-06-16 UY UY27854A patent/UY27854A1/es not_active IP Right Cessation
- 2003-06-17 MY MYPI20032252A patent/MY142354A/en unknown
- 2003-06-17 HN HN2003000184A patent/HN2003000184A/es unknown
- 2003-06-17 AR ARP030102141A patent/AR039688A1/es not_active Application Discontinuation
2004
- 2004-11-16 MA MA27953A patent/MA27205A1/fr unknown
- 2004-11-18 ZA ZA2004/09273A patent/ZA200409273B/en unknown
- 2004-12-08 CR CR7614A patent/CR7614A/es unknown
- 2004-12-15 EC EC2004005496A patent/ECSP045496A/es unknown
- 2004-12-15 IL IL165788A patent/IL165788A/en active IP Right Grant
- 2004-12-16 TN TNP2004000249A patent/TNSN04249A1/en unknown
2005
- 2005-01-04 NO NO20050036A patent/NO328567B1/no not_active IP Right Cessation
- 2005-03-25 US US11/089,777 patent/US7476652B2/en not_active Expired - Lifetime
2008
- 2008-12-04 US US12/328,208 patent/US7713930B2/en not_active Expired - Lifetime
2010
- 2010-05-04 US US12/773,356 patent/US20100216692A1/en not_active Abandoned
- 2010-10-15 JP JP2010232142A patent/JP2011006492A/ja active Pending
2013
- 2013-01-09 CY CY20131100021T patent/CY1113537T1/el unknown

Also Published As

Publication number	Publication date
ME00180B (me)	2010-10-10
CN102133393A (zh)	2011-07-27
HRP20041200B1 (hr)	2013-05-31
CN1662252A (zh)	2005-08-31
HN2003000184A (es)	2008-01-15
AR039688A1 (es)	2005-03-09
CY1113537T1 (el)	2016-06-22
MY142354A (en)	2010-11-15
WO2003105888A1 (fr)	2003-12-24
IL165788A0 (en)	2006-01-15
EP1517697B1 (fr)	2012-10-10
JP2005532365A (ja)	2005-10-27
UY27854A1 (es)	2003-12-31
TW200409642A (en)	2004-06-16
PL208773B1 (pl)	2011-06-30
BRPI0311877B1 (pt)	2017-04-11
PT1517697E (pt)	2012-12-17
EP2305288B1 (fr)	2020-07-15
EP1517697A1 (fr)	2005-03-30
OA12870A (en)	2006-09-15
AU2003238471B2 (en)	2009-02-19
NZ537211A (en)	2006-08-31
JP2011006492A (ja)	2011-01-13
RS105704A (sr)	2007-02-05
ZA200409273B (en)	2005-08-31
EP2305288A3 (fr)	2013-12-11
BRPI0311877B8 (pt)	2021-05-25
RU2005100959A (ru)	2005-06-27
BR0311877A (pt)	2005-04-05
ES2817879T3 (es)	2021-04-08
US20100216692A1 (en)	2010-08-26
US7476652B2 (en)	2009-01-13
HRP20041200A2 (en)	2005-06-30
EP2305288A2 (fr)	2011-04-06
UA79477C2 (en)	2007-06-25
DK1517697T3 (da)	2013-01-28
ES2397158T3 (es)	2013-03-05
RU2313362C2 (ru)	2007-12-27
PE20040560A1 (es)	2004-09-24
PL372072A1 (en)	2005-07-11
CA2490116A1 (fr)	2003-12-24
US20040048783A1 (en)	2004-03-11
MEP28708A (en)	2010-10-10
US20050171009A1 (en)	2005-08-04
ECSP045496A (es)	2005-03-10
PT2305288T (pt)	2020-09-16
US7713930B2 (en)	2010-05-11
CA2490116C (fr)	2012-07-24
TWI315201B (en)	2009-10-01
TNSN04249A1 (en)	2007-03-12
MXPA04012233A (es)	2005-02-25
NO20050036L (no)	2005-01-04
CN102133393B (zh)	2014-05-28
JP5237522B2 (ja)	2013-07-17
DE10227232A1 (de)	2004-01-15
IL165788A (en)	2011-05-31
US20090082255A1 (en)	2009-03-26
PA8575701A1 (es)	2004-02-07
RS52388B (sr)	2013-02-28
NO328567B1 (no)	2010-03-22
KR20050010939A (ko)	2005-01-28
SV2004001556A (es)	2004-03-08
KR101040029B1 (ko)	2011-06-10
AU2003238471A1 (en)	2003-12-31
CR7614A (es)	2005-06-16

Publication	Publication Date	Title
MA27205A1 (fr)	2005-01-03	Preparations d'insuline acides presentant une stabilite amelioree
FR13C0038I1 (fr)	2013-08-09	Nouveaux derives d'insuline
DE60106693D1 (de)	2004-12-02	Infusionspumpe
IS7043A (is)	2003-11-19	Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu
ATE535602T1 (de)	2011-12-15	Modifiziertes insulin mit reduzierter immunogenität
DK3210637T3 (da)	2021-04-06	Infusionssæt
EP1552833A4 (fr)	2008-12-03	Preparations solides stables
DE50214903D1 (de)	2011-03-24	Zinkfreie und zinkarme insulinzubereitungen mit verbesserter stabilität
ITRM20020133V0 (it)	2002-07-15	Complesso di elementi per l'assiemaggio di strutture.
FR2828243B1 (fr)	2006-06-30	Pompe
MA26804A1 (fr)	2004-12-20	Acides 3-propyl-gamma-aminobutyriques mono- et disubstitues.
EP1509598A4 (fr)	2006-05-10	Induction de l'expression de l'insuline
EP1484084A4 (fr)	2009-12-23	Structure d'electrode
EP1592438A4 (fr)	2009-07-08	Therapie d'administration orale d'insuline le soir
DE60304223D1 (de)	2006-05-11	Herstellung von metallamid-komplexen
DE60332885D1 (de)	2010-07-22	Haarwaschmittel enthaltend Hydroxymonocarbonsäuren
FR2834317B1 (fr)	2006-06-09	Pompe
DE60203605D1 (de)	2005-05-12	Reissverschlussverbinder
ATE434435T1 (de)	2009-07-15	Pharmazeutische zubereitungen enthaltend modafinil
NO20054662D0 (no)	2005-10-11	Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre
FR2885526B1 (fr)	2007-07-27	Medicament oral a base d'inhibiteur de pompe a protons
DE60108234D1 (de)	2005-02-10	Ladedruckpumpe
FR2824538B1 (fr)	2004-01-16	Pompe doseuse
FR2838790B1 (fr)	2005-11-04	Pompe
FR2815384B1 (fr)	2004-04-16	Pompe